Claims for Patent: 8,513,255

Summary for Patent: 8,513,255

Title:	Substituted dihydroquinazolines
Abstract:	The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
Inventor(s):	Tobias Wunberg, Judith Baumeister, Ulrich Betz, Mario Jeske, Thomas Lampe, Susanne Nikolic, Juergen Reefschlaeger, Rudolf Schohe-Loop, Frank Suessmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Joerg Keldenich, Dieter Lang, Peter Nell
Assignee:	AIC246 AG and Co KG
Application Number:	US11/728,896
Patent Claims:	1. A compound of formula (I): in which R1 represents hydrogen or methoxy; R3 represents halogen or trifluoromethyl; and R represents halogen or methoxy; or a salt thereof. 2. The compound of claim 1, wherein R3 represents fluorine, chlorine or trifluoromethyl; or a salt thereof. 3. The compound of claim 1, wherein R represents fluorine, chlorine or methoxy; or a salt thereof. 4. The compound of claim 1, wherein R is attached to the phenyl ring via the position meta or para to the point of attachment of the phenyl ring; or a salt thereof. 5. A compound {8-Fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazolin-4-yl}acetic acid, or a salt thereof. 6. A compound (S)-{8-Fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazolin-4-yl}acetic acid, or a salt thereof. 7. A process for preparing a compound of formula (I) according to claim 1, wherein a compound of formula (II): in which R1, R3 and R are as defined in claims 1; and R4 represents alkyl; is reacted with an acid or a base. 8. The process of claim 7, wherein R4 is methyl, ethyl or tert-butyl. 9. A medicament comprising a compound of claim 1, a compound of claim 5, or a compound of claim 6 in combination with at least one inert, non toxic, pharmaceutically acceptable excipient. 10. A method for the production of a medicament for the treatment of viral infections, comprising mixing a compound of claim 1, a compound of claim 5, or a compound of claim 6 with at least one inert, non toxic, pharmaceutically acceptable excipient. 11. The method of claim 10, wherein the viral infection is an infection with the human cytomegalovirus (HCMV) or another representative of the group of the Herpes viridae. 12. A method for treating infections HO—C(═O)—CH2— at the 4-position; in humans and animals, comprising administering an antivirally effective amount of a compound of claim 1, a compound of claim 5, or a compound of claim 6, to a human or animal in need thereof. 13. A method for treating infections HO—C(═O)—CH2— at the 4-position; in humans and animals, comprising administering an antivirally effective amount of a medicament of claim 9 to a human or animal in need thereof.